Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.

Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.